When Psilocybin Meet Silicon Valley. The second panel discussion at 7 October’s PSYCH Investor Summit: Data & Technology centred on the value and adoption of applications that monitor patients before, during and after psychedelic assisted therapy. The discussion was moderated by Business Insider’s psychedelic industry journalist Yeji Jesse Lee.
Kelsey Ramsden, CEO at MINDCURE, was joined by FIeld Trip Health’s Executive Chairman Ronan Levy and Dr Reid Robison, Chief Medical Officer at Novamind.
About Kelsey Ramsden, CEO at MINDCURE:
Kelsey has over 15 years of experience founding, scaling, and operating innovative companies across Canada and the Caribbean. She has built multiple 8-figure businesses from the ground up and has twice been named Canada’s Top Female Entrepreneur. Kelsey also serves on the Entrepreneurship Council for the University of Western Ontario, where she is also a faculty member teaching Design Thinking. Kelsey holds an MBA from the Richard Ivey School of Business at the University of Western Ontario.
About Ronan Levy, Executive Chairman at Field Trip Health:
An entrepreneur and a visionary, Ronan is one the Founders of Field Trip. Concurrent with his work at Field Trip, he is a partner at Grassfed Ventures, a venture capital and advisory firm focused on the cannabis and biotech industries and is Chief Strategy Officer and Member of the Board of Directors for Trait Biosciences Inc., a leading biotech company in the hemp and cannabis industries.
About Dr Reid Robison, Chief Medical Officer at Novamind:
Reid Robison is a Director and Chief Medical Officer at Novamind, in addition to being the Co-founder of Cedar Psychiatry. Dr. Robison serves as Coordinating Investigator of the MAPS (Multidisciplinary Association for Psychedelic Studies) MDMA-Assisted Psychotherapy study of Eating Disorders, supervising the training and clinical research of all of the MDMA therapy sites.
About Yeji Jesse Lee, Journalist at Business Insider:
Yeji Jesse Lee covers psychedelic and cannabis industry news for Business Insider. Once New York became the epicentre of the novel coronavirus earlier this year, she also covered the healthcare industry, interviewing doctors and other healthcare professionals on the frontlines of caring for COVID-19 patients.
PSYCH is a premium business-to-business media and content platform for the psychedelic science and healthcare industry.
As our collective understanding of and attitudes towards psychedelics shift dramatically, we are witnessing a global rise in clinical trials, academic research and commercial investment. PSYCH tracks key psychedelic players, innovations and milestones, providing market insights to help investors make informed decisions.
Psychedelics are poised to disrupt the way we approach healthcare. To learn more about PSYCH, access our industry-leading events, subscribe to the most widely read psychedelics industry newsletter, or download The Psychedelics as Medicine Report.